Literature DB >> 2297700

Tumor necrosis factor in children with malignancies.

U M Saarinen1, E K Koskelo, A M Teppo, M A Siimes.   

Abstract

We measured serum tumor necrosis factor alpha (TNF) concentrations by a double-antibody radioimmunoassay method, with a detection level of 10 ng/liter, in 32 children with malignancies. Seventeen had acute lymphoblastic leukemia, 4 had acute nonlymphocytic leukemia, and 11 had solid tumors. At the diagnosis of malignant disease, 30 of the 32 patients had elevated serum TNF levels ranging up to 450 ng/liter. After complete remission status was achieved, 2-6 months from the diagnosis, the TNF levels were within the range of 130 healthy children who served as the reference group. Most of them had TNF levels below the detection limit. We consider the upper limit of normal to be 40 ng/liter. We conclude that elevated serum TNF concentration may be of potential significance in the diagnosis and follow-up of children with malignant diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297700

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Tumor necrosis factor alpha in children with sickle cell disease in stable condition.

Authors:  S Kuvibidila; R Gardner; D Ode; L Yu; G Lane; R P Warrier
Journal:  J Natl Med Assoc       Date:  1997-09       Impact factor: 1.798

3.  Association between increased levels of TNF-alpha, decreased levels of prealbumin and retinol-binding protein, and disease outcome.

Authors:  S Kuvibidila; L Yu; R Gardner; M Velez; D Ode; R P Warrier
Journal:  J Natl Med Assoc       Date:  2000-10       Impact factor: 1.798

4.  Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication.

Authors:  A Trulson; S Nilsson; P Venge
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

5.  Increased muscle proteasome activity correlates with disease severity in gastric cancer patients.

Authors:  Maurizio Bossola; Maurizio Muscaritoli; Paola Costelli; Gabriella Grieco; Gabriella Bonelli; Fabio Pacelli; Filippo Rossi Fanelli; Giovanni Battista Doglietto; Francesco Maria Baccino
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

6.  Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry.

Authors:  Z Bebök; B Márkus; P Németh
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Acute metabolic effects of human recombinant tumor necrosis factor beta in the rat.

Authors:  D Blumberg; A Tsuburaya; M Burt; D B Donner; M F Brennan
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

8.  Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer.

Authors:  R Partanen; H Koskinen; K Hemminki
Journal:  Occup Environ Med       Date:  1995-05       Impact factor: 4.402

9.  Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.

Authors:  J Punnonen; P K Heinonen; T Kuoppala; C T Jansen; R Punnonen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.

Authors:  P Cariuk; M J Lorite; P T Todorov; W N Field; S J Wigmore; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.